Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock
Preetam Shah Insider Alerts

Get notified the next time Preetam Shah buys or sells Cidara Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Preetam Shah Insider Information



Founder of Saisarva LLC, Preetam Shah presently is Chief Financial & Business Officer at Cidara Therapeutics, Inc.

In the past Dr. Shah was Vice President-U.S. Operations & Investments at Reliance Capital Usa Ventures LLC, Chief Financial Officer, Treasurer & Executive VP of Brainstorm Cell Therapeutics, Inc., Director-Healthcare Investment Banking at Barclays Capital, Inc., Director-Healthcare Investment Banking at Lordes Capital Ltd. and Vice President-Healthcare Investment Banking at Canaccord Genuity, Inc.

Preetam Shah received an MBA from The Wharton School of the University of Pennsylvania and a doctorate from the University of Mississippi Medical Center.

How do I contact Preetam Shah?

The corporate mailing address for Dr. Shah and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]

Has Preetam Shah been buying or selling shares of Cidara Therapeutics?

During the last ninety days, Preetam Shah has bought $30,800.00 in Cidara Therapeutics stock. Most recently, on Friday, November 12th, Preetam Shah bought 20,000 shares of Cidara Therapeutics stock. The stock was acquired at an average cost of $1.54 per share, with a total value of $30,800.00.

Who are Cidara Therapeutics' active insiders?

Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Jessica Oien (General Counsel), Preetam Shah (CFO), and Jeffrey Stein (CEO).

Are insiders buying or selling shares of Cidara Therapeutics?

In the last twelve months, Cidara Therapeutics insiders bought shares 4 times. They purchased a total of 117,000 shares worth more than $193,940.00. In the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 6,931 shares worth more than $16,221.26. The most recent insider tranaction occured on November, 12th when CEO Jeffrey Stein bought 50,000 shares worth more than $79,500.00. Insiders at Cidara Therapeutics own 8.0 % of the company.

Information on this page was last updated on 11/12/2021.

Preetam Shah Insider Trading History at Cidara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/12/2021Buy20,000$1.54$30,800.00View SEC Filing Icon  
See Full Table

Preetam Shah Buying and Selling Activity at Cidara Therapeutics

This chart shows Preetam Shah's buying and selling at Cidara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cidara Therapeutics Company Overview

Cidara Therapeutics logo
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $1.43
Low: $1.42
High: $1.49

50 Day Range

MA: $1.73
Low: $1.40
High: $2.35

2 Week Range

Now: $1.43
Low: $1.31
High: $3.15

Volume

501,939 shs

Average Volume

697,794 shs

Market Capitalization

$95.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock